Atenolol
- Atc Codes:C07AB03
- CAS Codes:29122-68-7
- PHARMGKB ID:29122-68-7
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Atehexal, Atenolan, Atenolol, Tenormin; Belgium: Atenolol, Docateno, Tenormin; Bulgaria: Atenolol, Tenormin, Tredol; Cyprus: Atehexal, Atenolol, Blokium, Neocardon, Tenormin, Tredol, Vascoten, Velorin; Czech Republic: Apo-Atenol, Atehexal, Atenobene, Atenolol, Tenormin; Denmark: Atenet, Atenodan, Atenolol, Atenor, Tenormin, Uniloc; Estonia: Atenolol; Finland: Atenblock, Atenolol, Tenoblock, Tenoprin; France: Atenolol, Tenormine; Germany: Ate Lich, Atebeta, Atehexal, Atendol, Atenogamma, Atereal, Cuxanorm, Duratenol, Hypernel, Jenatenol, Juvental, Tenormin; Greece: Atenolol, Azectol, Blikonol, Neocardon, Synarome, Tenormin; Hungary: Atenobene, Atenolol, Atenomel, Prinorm; Ireland: Amolin, Atecor, Ateni, Atenogen, Atenomel, Nortenolol, Tenormin; Italy: Atenol, Atenololo, Seles Beta, Tenomax, Tenormin, Tensiblock; Latvia: Atenolol; Lithuania: Atenolol; Luxembourg: Atefim, Atehexal, Atenolol, Atenomed, Atenotop, Atephar, Athenol, Blokium, Docateno, Tenolol, Tenormin; Malta: Mesonex, Tenormin, Tensol, Totamol, Tredol; Netherlands: Atenolol, Tenormin, Unibloc; Poland: Apo-Atenol, Atehexal, Atendol, Atenolol, Normocard, Tenormin; Portugal: Atenolol, Tenormin; Romania: Atecor, Atenocor, Atenolol, Vascoten; Slovakia: Atehexal, Atenolol, Atenobene; Slovenia: Atenolol, Ormidol, Tenormin; Spain: Atenolol, Blokium, Neatenol, Tanser, Tenormin; Sweden: Atenolol, Tenormin; UK: Atenolol, Tenormin.
North America
Canada: Apo-Atenol, Atenolol, Tenormin; USA: Tenormin.
Latin America
Argentina: Atelán, Atenoblock, Atenolol, Atenopharma, Atenovit, Cardioblock, Corpaz, Fabotenol, Felobits, Ilatén, Myocord, Plenacor, Prenormine, Telvodín, Tozoldén, Vericordín; Brazil: Ablok, Angipress, Atenegran, Ateneo, Atenobal, Atenokin, Atenol, Atenolab, Atenolol, Aternorm, Atensiol, Atenuol, Atepress, Plenacor; Mexico: Atenolol, Atokén, Biofilén, Blotex, Lesaten, Min-T, Nosbal, Tenormín, Trebanol.
Asia
Japan: Alcenol, Almylar, Atendal, Atenemeal, Atenolol, Atenorhythm, Atenosafe, Dolru, Fellfish, Hajime, Katenomin, Kushisemin, Lismories, Mecrol, Metinin, Mezolmin, Mirobect, Originol, Sailagile, Savetens, Tenomilol, Tenormin, Towamin.
Drug combinations
Atenolol and Chlorthalidone
Atenolol and Hydrochlorothiazide
Atenolol and Nifedipine
Atenolol, Amiloride, and Hydrochlorothiazide
Atenolol, Chlorthalidone, and Hydralazine
Chemistry
Atenolol: C~14~H~22~N~2~O~3~. Mw: 266.34. (1) Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-; (2) 2-[p-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide. CAS-29122-68-7 (1976).
Pharmacologic Category
Cardiovascular Drugs; β-Adrenergic Blocking Agents; β~1~-Selective β-Blocker. (ATC-Code: C07AB03).
Mechanism of action
Competitively blocks response to β-adrenergic stimulation, selectively blocks β~1~-receptors with little or no effect on β~2~-receptors except at high doses.
Therapeutic use
Treatment of hypertension. Management of angina pectoris, postmyocardial infarction.
Pregnancy and lactiation implications
Atenolol crosses the placenta. β-Blockers have been associated with persistent bradycardia, hypotension, and intrauterine growth retardation (probably related to maternal hypertension). Cases of neonatal hypoglycemia reported following maternal use of β-blockers at parturition or during breast-feeding. Use with caution during lactation.
Unlabeled use
Acute ethanol withdrawal. Supraventricular and ventricular arrhythmias. Migraine. Headache prophylaxis.
Contraindications
Hypersensitivity to atenolol or any component of the formulation. Sinus bradycardia. Sinus node dysfunction. Heart block greater than first-degree (except with a functioning artificial pacemaker). Cardiogenic shock. Uncompensated cardiac failure. Pulmonary edema. Pregnancy.
Warnings and precautions
Use caution with history of severe anaphylaxis to allergens. β-Blockers should be avoided in bronchospastic disease. Atenolol, with β~1~-selectivity, has been used cautiously. Consider pre-existing conditions such as sick sinus syndrome before initiating. Use with caution in diabetes mellitus (may mask hypoglycemic symptoms), heart failure, myasthenia gravis, peripheral vascular disease (including Raynaud’s), psychiatric illness (may cause CNS depression), or in renal impairment. Adequate α-blockade is required prior to use of any β-blocker in untreated pheochromocytoma. Use care with anesthetic agents which decrease myocardial function. Use caution with concurrent use of β-blockers and either verapamil or diltiazem (bradycardia or heart block can occur). Therapy should not be withdrawn abruptly (to avoid acute tachycardia, hypertension, and/or ischemia).